Heska Corporation (NASDAQ:HSKA) management will conduct a conference call for 4th August 2020 at 11:00 AM Eastern Time to discuss financial results and companys performance for 2Q20.
The conference call will also be available live on the website www.heska.com
Earnings Expectation
Heska Corporation veterinary diagnostic specialist, is reporting second quarter earnings results on Tuesday 4th August 2020, before market open. The consensus estimates from Thomson Reuters are loss of $ 0.34 per share. For the full year, analysts predict revenues of $ 175.66 million, while looking forward to loss of $ 1.02 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 175.00 million ~ $ 185.00 million
Click Here For More Historical Outlooks Of Heska Corporation
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The companys Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops.
